Answers are grounded in this paper and cite their sources.
In 2016, surgery is the standard of care for peripheral stage I non-small cell lung cancer. However, recent thought-provoking randomized evidence suggests stereotactic ablative body radiotherapy (SABR) has survival outcomes similar to those of surgery. Albeit limited, patient-reported outcomes and quality of life suggest that SABR compares favorably to surgery because it is noninvasive and associated with relatively few treatment-related complications. This article explores the current scientific landscape of surgery and SABR in this patient cohort.
No takes yet. Share an insight, caveat, or question.
Siva et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: